Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab

NCT01235897 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01235897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01235897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
November 30, 2013
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, cancer, tumors